
Please try another search
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for type 1 diabetes, diabetic retinopathy, and diabetic neuropathy; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; and Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy. The company also offers analytical services, such as specialist contract research focusing on biomarker discovery, biosimilars quality control, and pharmacokinetic testing for clinical trials. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Perth, Australia.
Name | Age | Since | Title |
---|---|---|---|
Terry Sweet | 74 | 2014 | Independent Non-Executive Chairman |
Neil Sholnik | - | - | Member of Clinical Advisory Board |
Merlin Thomas | - | 2022 | Member of Clinical Advisory Board |
Eleuterio Ferrannini | - | 2022 | Member of Clinical Advisory Board |
Michael Shanik | - | 2022 | Member of Clinical Advisory Board |
Alexander Turchin | - | 2022 | Member of Clinical Advisory Board |
Tim Davis | - | 2022 | Member of Clinical Advisory Board |
Davida F. Kruger | - | - | Member of Clinical Advisory Board |
Paul House | 54 | 2017 | Independent Non-Executive Director |
Neville Gardiner | - | 2021 | Independent Non-Executive Director |
Richard John Lipscombe | - | 2001 | Co-Founder, MD & Director |
James Williams | - | 2024 | Independent Non- Executive Chairman |
Aaron Brinkworth | - | 2024 | Independent Non-Executive Director |
Prasad Iyer | - | 2025 | Member of Clinical Advisory Board |
Andrew Chang | - | 2025 | Member of Clinical Advisory Board |
Krish Ragunath | - | 2025 | Member of Clinical Advisory Board |
Jacques Bergman | - | 2025 | Member of Clinical Advisory Board |
Robert Odze | - | 2025 | Member Clinical Advisory Board |
Daniela Molena | - | 2025 | Member of Clinical Advisory Board |
Hugh Barr | - | 2025 | Member of Clinical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review